Glenmark Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
The unexpected GST regime change caused a one-time reduction in distributor inventories, impacting primary sales. While management expects normalization, future regulatory changes could again disrupt the three-tier model.
Analysts questioned the frequency of write-offs (Monroe, litigation, India). Management assured no further corrections, but past unpredictability raises concerns about controls.
Management confirmed litigation cash outflows of slightly less than INR 800 crore over the next few years, which could pressure cash flows if not managed.
